Evaluation of the clinical efficacy of adding metformin to chemotherapy regimen for patients with ovarian cancers

Trial ID # IRCT2016022726788N1
Phase II
Drug Class Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR
Drug Name Metformin
Alternate Drug Names Riomet, Glumetza, Glucophage, Fortamet
Drugs in Trial Carboplatin, Metformin, Paclitaxel
Eligible Participant

Newly diagnosed stage I-III ovarian cancer

Patients Enrolled

70

Therapy Setting

First-line

Study Design

Open-Label, Randomized

Endpoints

RFS, evaluated per CA125

Efficacy

CarboPt+Pac+Met (n=30) vs CarboPt+Pac (n=40):

RFS: 48.0 vs 25.7 months

4-year rate of recurrence: 13.3 vs 67.5%

Clinically Significant Adverse Events

CarboPt+Pac+Met vs CarboPt+Pac:
Grade 1-4 AE: abdominal discomfort (20 vs 0%)

Conclusion

Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients

Reference

Hamedi B et al. Combination of Metformin and Chemotherapy Decreases the Recurrence Rates of Epithelial Ovarian Cancers: A Randomized Clinical Trial. Int J Cancer Manag (2018) 11(7): e11621
http://intjcancermanag.com/en/articles/11621.html